• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mult Scler Relat Disord . Frequency and Severity of COVID-19 in Multiple Sclerosis: A Short Single-Site Report From Northern Italy

tetano

tetano

Editor, Senior Moderator
Mult Scler Relat Disord


. 2020 Jul 4;44:102372.
doi: 10.1016/j.msard.2020.102372. Online ahead of print.
Frequency and Severity of COVID-19 in Multiple Sclerosis: A Short Single-Site Report From Northern Italy


Francesco Crescenzo[SUP] 1 [/SUP], Damiano Marastoni[SUP] 1 [/SUP], Chiara Bovo[SUP] 2 [/SUP], Massimiliano Calabrese[SUP] 3 [/SUP]



Affiliations

Abstract

Neurologists are interested in understanding whether patients with multiple sclerosis (pwMS) undergoing immunomodulatory/immunosuppressive therapy are more susceptible to developing COVID-19 or have worse outcomes. Currently, there are no conclusive data in this regard. We report the prevalence and severity of COVID-19 (confirmed and possible) in pwMS followed at the Veneto Regional MS Center in Verona (Italy), an area most stricken by COVID-19. In our sample size, the prevalence of COVID-19 seems to be much higher than that officially reported at the regional level on the general population, but it also characterized by a favourable course.

Keywords: COVID-19; coronavirus; multiple sclerosis.
 
You must log in or register to reply here.
Back
Top Bottom